# Plasma Cell Myeloma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/plasma-cell-myeloma

> 6 upcoming FDA catalysts in plasma Cell Myeloma: isatuximab sar650984 (SNY) on Apr to Jul 2027 (topline data readout); isatuximab sar650984 (SNY) on April 2027 (primary completion); isatuximab intravenous (iv, SNY) on Nov 2028 to Feb 2029 (topline data readout); isatuximab intravenous (iv, SNY) on November 2028 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr to Jul 2027 | [Isatuximab sar650984 topline data readout](https://sec-api.dev/pdufa/isatuximab-sar650984) | SNY | Plasma Cell Myeloma | scheduled | "NCT03319667 (A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-05 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03319667)) |
| April 2027 | [Isatuximab sar650984 primary completion](https://sec-api.dev/pdufa/isatuximab-sar650984) | SNY | Plasma Cell Myeloma | scheduled | "NCT03319667 (A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-05 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03319667)) |
| Nov 2028 to Feb 2029 | [Isatuximab intravenous (iv) topline data readout](https://sec-api.dev/pdufa/isatuximab-intravenous-iv) | SNY | Plasma Cell Myeloma | scheduled | "NCT05669989 (International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05669989)) |
| November 2028 | [Isatuximab intravenous (iv) primary completion](https://sec-api.dev/pdufa/isatuximab-intravenous-iv) | SNY | Plasma Cell Myeloma | scheduled | "NCT05669989 (International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05669989)) |
| Oct 2030 to Jan 2031 | [Isatuximab sar650984 topline data readout](https://sec-api.dev/pdufa/isatuximab-sar650984) | SNY | Plasma Cell Myeloma | scheduled | "NCT04270409 (Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-10-14 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04270409)) |
| October 2030 | [Isatuximab sar650984 primary completion](https://sec-api.dev/pdufa/isatuximab-sar650984) | SNY | Plasma Cell Myeloma | scheduled | "NCT04270409 (Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-10-14 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04270409)) |

## Drugs

- [Isatuximab sar650984](https://sec-api.dev/pdufa/isatuximab-sar650984) (SNY)
- [Isatuximab intravenous (iv)](https://sec-api.dev/pdufa/isatuximab-intravenous-iv) (SNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/plasma-cell-myeloma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Plasma Cell Myeloma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/plasma-cell-myeloma

```bibtex
@misc{secapidev_indications_plasma_cell_myeloma_20261116,
  title        = {Plasma Cell Myeloma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/plasma-cell-myeloma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_plasma_cell_myeloma_20261116","title":"Plasma Cell Myeloma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/plasma-cell-myeloma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
